Table 4.
The frequencies of lenvatinib-induced adverse events between genotypes of ABC transporters and CYP3A4/5.
| Adverse events | Hypertension | P value | Proteinuria | P value | Hand-foot syndrome | P value | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CTCAE grade | 0 | 1 | 2 | 3 | 0 | 1 | 2 | 3 | 0 | 1 | 2 | |||
| ABCB1 1236C>T | ||||||||||||||
| C/C | 0 | 4 | 3 | 1 | 0.140 | 3 | 2 | 3 | 0 | 0.599 | 0 | 6 | 2 | 0.431 |
| C/T | 0 | 3 | 16 | 3 | 11 | 3 | 6 | 2 | 0 | 14 | 8 | |||
| T/T | 0 | 1 | 6 | 3 | 6 | 3 | 1 | 0 | 1 | 7 | 2 | |||
| ABCB1 2677G>T/A | ||||||||||||||
| G/G | 0 | 0 | 8 | 1 | 0.211 | 3 | 2 | 4 | 0 | 0.387 | 0 | 7 | 2 | 0.702 |
| G/T + G/A | 0 | 4 | 10 | 5 | 11 | 4 | 2 | 2 | 1 | 11 | 7 | |||
| T/T + T/A + A/A | 0 | 4 | 7 | 1 | 6 | 2 | 4 | 0 | 0 | 9 | 3 | |||
| ABCB1 3435C>T | ||||||||||||||
| C/C | 0 | 3 | 10 | 1 | 0.798 | 4 | 3 | 7 | 0 | 0.093 | 0 | 13 | 1 | 0.150 |
| C/T | 0 | 4 | 12 | 5 | 13 | 3 | 3 | 2 | 1 | 11 | 9 | |||
| T/T | 0 | 1 | 3 | 1 | 3 | 2 | 0 | 0 | 0 | 3 | 2 | |||
| ABCG2 421C>A | ||||||||||||||
| C/C | 0 | 5 | 11 | 4 | 0.606 | 11 | 4 | 4 | 1 | 0.896 | 0 | 14 | 6 | 0.595 |
| C/A + A/A | 0 | 3 | 14 | 3 | 9 | 4 | 6 | 1 | 1 | 13 | 6 | |||
| ABCC2 −24C>T | ||||||||||||||
| C/C | 0 | 3 | 17 | 4 | 0.305 | 11 | 5 | 7 | 1 | 0.866 | 1 | 15 | 8 | 0.574 |
| C/T + T/T | 0 | 5 | 8 | 3 | 9 | 3 | 3 | 1 | 0 | 12 | 4 | |||
| CYP3A4 20230G>A( *1G ) | ||||||||||||||
| *1/*1 | 0 | 6 | 14 | 4 | 0.625 | 14 | 3 | 6 | 1 | 0.457 | 1 | 14 | 9 | 0.281 |
| *1/*1G + *1G/*1G | 0 | 2 | 11 | 3 | 6 | 5 | 4 | 1 | 0 | 13 | 3 | |||
| CYP3A5 6986A>G(*3) | ||||||||||||||
| *1/*1 + *1/*3 | 0 | 3 | 9 | 2 | 0.923 | 5 | 4 | 4 | 1 | 0.577 | 0 | 12 | 2 | 0.185 |
| *3/*3 | 0 | 5 | 16 | 5 | 15 | 4 | 6 | 1 | 1 | 15 | 10 | |||
Data are presented as patients numbers.